AKBA vs CUBE · rev $160.2M vs P/E 25, rev $1.07B
Akebia Ther (AKBA) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
Akebia Ther (AKBA) is a drug manufacturers - specialty & generic company listed on US.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Latest reported AKBA revenue for 2024-12-31 was $160.2M. Net income was -$69.4M. Revenue was down 17.7% from 2023-12-31 to 2024-12-31. AKBA currently screens at market cap $260.1M.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
AKBA currently screens at market cap $260.1M. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the AKBA and CUBE stock pages for the full models.
Not investment advice.